A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a confirmed diagnosis of stage IV squamous NSCLC
Participant must have progressed during or after platinum-based chemotherapy
Participant must be fully active or if restricted in physically strenuous activity should be able to walk and carry out light work, e.g., light house work, office work
Participant must agree to use a reliable medically approved method of birth control
Participants Must Not:
Participant must not have received prior treatment with docetaxel
Participant must not have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor where the treatment administered is not known
Participant must not be currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo